Trials / Unknown
UnknownNCT04989322
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
A Phase 2 Open-label Single-arm Study to Evaluate the Combination of Pembrolizumab, Lenvatinib and Chemotherapy in Non-small Cell Lung Cancer (NSCLC) Harbouring Targetable Mutation and Failed Standard Tyrosine Kinase Inhibitors
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Dr Joanne CHIU · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Adding chemotherapy or anti-VEGF to immunotherapy is an emerging strategy to enhance the efficacy of immunotherapy in many cancers. This phase 2 study aims to explore the preliminary efficacy of combination pembrolizumab with lenvatinib and chemotherapy in NSCLC patients with sensitizing EGFR, ALK, or ROS1 genetic aberration refractory to standard targeted therapy.
Conditions
- Nsclc
- EGFR Activating Mutation
- EGF-R Positive Non-Small Cell Lung Cancer
- ALK Gene Rearrangement Positive
- ROS1 Gene Rearrangement
- ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | 200 mg Q3W |
| DRUG | Lenvatinib | 8 mg daily |
| DRUG | Pemetrexed | 500 mg/m2 Q3W |
| DRUG | Carboplatin | AUC5 Q3W |
Timeline
- Start date
- 2021-10-05
- Primary completion
- 2024-08-01
- Completion
- 2024-12-01
- First posted
- 2021-08-04
- Last updated
- 2021-12-08
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT04989322. Inclusion in this directory is not an endorsement.